Gilead Sciences Inc
NASDAQ: GILD
$69.61
-$1.12 (-1.6%)
Closing Price on June 25, 2024
GILD Articles
Earnings season is in full swing, and we have put together a preview of some of the world’s largest players in the health care sector reporting this coming week.
Published:
Tuesday's top analyst upgrades and downgrades included Airbnb, American Express, Arch Capital, Carlyle, Darden Restaurants, Facebook, Eli Lilly and Nio.
Published:
As earnings season begins, Lululemon Athletica and other companies are updating guidance for the quarter just ended and for the 2020 fiscal year.
Published:
Although the markets may be falling, 24/7 Wall St. is taking a look at some big analyst calls that we have seen so far on Monday.
Published:
Thursday's top analyst upgrades and downgrades included AT&T, Boeing, ConocoPhillips, Gilead Sciences, Illumina, Lam Research, Raytheon Technologies and Yum Brands.
Published:
Galapagos was crushed on Wednesday after the firm, in conjunction with Gilead, announced a new commercialization and development agreement for their Rheumatoid Arthritis (RA) treatment.
Published:
The November 30 short interest data has been compared with the previous report, and short interest moves in these selected biotech stocks were mixed.
Published:
The November 13 short interest data has been compared with the previous report, and short interest in most of these selected biotech stocks decreased.
Published:
Here is an update on the stocks of each major player in the COVID-19 arena, including brief trading histories and consensus price targets.
Published:
Thursday's top analyst upgrades and downgrades included Amgen, Boeing, eBay, Etsy, Fastly, Fiverr, Ford, General Electric, Gilead Sciences, Pinterest and Six Flags.
Published:
Amgen and Gilead released their most recent financial results after the closing bell on Wednesday.
Published:
The October 15 short interest data has been compared with the previous report, and short interest moves in these selected biotech stocks were mixed.
Published:
Gilead Sciences is the first company to cross the finish line for regulatory approval in the fight against the coronavirus.
Published:
Some battered stocks that have not risen back to their highs are attracting some interesting analyst upgrades and new coverage.
Published:
The September 30 short interest data has been compared with the previous report, and short interest moves in these selected biotech stocks were mixed.
Published: